ReviewFrontiers in pharmacology2021
Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Cardioprotective Effects of Ling-Gui-Zhu-Gan Decoction Against Ventricular Remodeling after Acute Myocardial Infarction via ROS/TXNIP/NLRP3 Signaling.Chinese journal of integrative medicine · 2026Article
- The Potential Role of Dietary (Poly)phenols in Cardiometabolic Risk During Menopause: A Narrative Review.Nutrients · 2026Review
- Quantitative Analysis of Flavonols and Their Glycosides and Gastrointestinal Transformation of Flavonol Glycosides in Yinxing Mihuan Oral Solution.Journal of analytical methods in chemistry · 2026Article
- Microbiota-mediated mechanisms of natural products in atherosclerosis: focus on metabolic and inflammatory pathways.Frontiers in endocrinology · 2026Review
- Regulatory effect ofJournal of advanced veterinary and animal research · 2026Article
- Metabolomics analysis of antioxidant and lipid-lowering activities, colonic fermentation properties of quinoa bran polyphenol extract during in vitro digestion.NPJ science of food · 2025Article
- Cardiovascular protective effects of natural flavonoids on intestinal barrier injury.Molecular and cellular biochemistry · 2025Review
- Review
- The Protective Effect of Flavonoids in the Diet on Autophagy-Related Cardiac Impairment.Nutrients · 2024Review
- Microbiota Metabolism Failure as a Risk Factor for Postoperative Complications after Aortic Prosthetics.Biomedicines · 2023Article
- Modulation of gut microbiota by foods and herbs to prevent cardiovascular diseases.Journal of traditional and complementary medicine · 2023Review
- Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Malnourished Microbiome: American's #1 Nutritional Deficiency.Integrative medicine (Encinitas, Calif.) · 2022Article
- Microbiota in health and diseases.Signal transduction and targeted therapy · 2022Review
- Adeno-associated virus vector intraperitoneal injection induces colonic mucosa and submucosa transduction and alters the diversity and composition of the faecal microbiota in rats.Frontiers in cellular and infection microbiology · 2022Article
- Gut Microbiota as Early Predictor of Infectious Complications before Cardiac Surgery: A Prospective Pilot Study.Journal of personalized medicine · 2021Article
- Microbiota and Myopericarditis: The New Frontier in the Car-Diological Field to Prevent or Treat Inflammatory Cardiomyo-Pathies in COVID-19 Outbreak.Biomedicines · 2021Review
- Radiotherapy-Induced Digestive Injury: Diagnosis, Treatment and Mechanisms.Frontiers in oncology · 2021Review
- Attenuation of Circulating Trimethylamine N-Oxide Prevents the Progression of Cardiac and Renal Dysfunction in a Rat Model of Chronic Cardiorenal Syndrome.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the main cause of death worldwide, and traditional cardiovascular risk factors cannot fully explain the occurrence of the disease. In recent years, the relationship between gut microbiota and its metabolites and cardiovascular disease has been a hot study topic. The changes in gut microbiota and its metabolites are related to the occurrence and development of atherosclerosis, myocardial infarction, heart failure, and hypertension. The mechanisms by which gut microbiota and its metabolites influence cardiovascular disease have been reported, although not comprehensively. Additionally, following ingestion, flavonoids are decomposed into phenolic acids that are more easily absorbed by the body after being processed by enzymes produced by intestinal microorganisms, which increases flavonoid bioavailability and activity, consequently affecting the onset of cardiovascular disease. However, flavonoids can also inhibit the growth of harmful microorganisms, promote the proliferation of beneficial microorganisms, and maintain the balance of gut microbiota. Hence, it is important to study the relationship between gut microbiota and flavonoids to elucidate the protective effects of flavonoids in cardiovascular diseases. This article will review the role and mechanism of gut microbiota and its metabolites in the occurrence and development of atherosclerosis, myocardial infarction, heart failure, and hypertension. It also discusses the potential value of flavonoids in the prevention and treatment of cardiovascular disease following their transformation through gut microbiota metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.